1. Scrip
  2. >>Business

Novartis Is Dialing Out Of Its Listed Indian Arm – The Possibilities

 
• By Anju Ghangurde

Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.

Novartis reviews options for listed Indian arm • Source: Shutterstock

Way back in March 1996, Swiss pharmaceutical companies Ciba-Geigy and Sandoz. decided to merge and form what was then the world’s biggest life sciences combine christened Novartis.

Key Takeaways

  • Novartis AG initiates strategic review of listed entity in India

  • Swiss parent to assess 70.68% holding in Indian arm

  • Novartis India Ltd has seen successive top-level exits over the years

The India merger of local arms Hindustan Ciba-Geigy Limited and Sandoz (India) Limited came a year on, post various approvals and Novartis

More from Business

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

More from Scrip

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.